Home > Publications database > Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL. > print

001     307241
005     20251216120119.0
024 7 _ |a 10.1182/bloodadvances.2025017770
|2 doi
024 7 _ |a pmid:41026972
|2 pmid
024 7 _ |a 2473-9529
|2 ISSN
024 7 _ |a 2473-9537
|2 ISSN
037 _ _ |a DKFZ-2025-02934
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Roerden, Malte
|0 0000-0001-7283-9778
|b 0
245 _ _ |a Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.
260 _ _ |a Washington, DC
|c 2025
|b American Society of Hematology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765808501_1896239
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Hensen, Luca
|0 0000-0001-8467-8537
|b 1
700 1 _ |a Besemer, Britta
|b 2
700 1 _ |a Schwartz, Friederike
|0 0000-0003-4709-3956
|b 3
700 1 _ |a Reuss, Kristina
|b 4
700 1 _ |a Weiss-Haug, Alisha
|b 5
700 1 _ |a Harland, Lennart
|0 0009-0004-6430-051X
|b 6
700 1 _ |a Ginsberg, Franziska
|b 7
700 1 _ |a Faul, Christoph
|b 8
700 1 _ |a Bethge, Wolfgang
|0 0000-0001-6052-2618
|b 9
700 1 _ |a Lengerke, Claudia
|0 0000-0001-5442-2805
|b 10
773 _ _ |a 10.1182/bloodadvances.2025017770
|g Vol. 9, no. 24, p. 6340 - 6344
|0 PERI:(DE-600)2876449-3
|n 24
|p 6340 - 6344
|t Blood advances
|v 9
|y 2025
|x 2473-9529
909 C O |o oai:inrepo02.dkfz.de:307241
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 0000-0001-5442-2805
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD ADV : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-05T12:07:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-05T12:07:28Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-07-05T12:07:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BLOOD ADV : 2022
|d 2024-12-16
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
920 1 _ |0 I:(DE-He78)TU01-20160331
|k TU01
|l DKTK Koordinierungsstelle Tübingen
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)TU01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21